134,627 Biogen Inc. $BIIB Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 17.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 656,465 shares of the biotechnology company's stock after selling 134,627 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.44% of Biogen worth $148,282,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG boosted its position in shares of Biogen by 5.7% in the 3rd quarter. Bank Pictet & Cie Europe AG now owns 3,279 shares of the biotechnology company's stock valued at $741,000 after purchasing an additional 176 shares during the period. Prime Capital Investment Advisors LLC increased its position in Biogen by 776.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 21,271 shares of the biotechnology company's stock worth $4,805,000 after buying an additional 18,844 shares during the period. Investors Asset Management of Georgia Inc. GA ADV increased its position in Biogen by 811.3% during the third quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 9,405 shares of the biotechnology company's stock worth $2,124,000 after buying an additional 8,373 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Biogen by 1,552.4% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 345,619 shares of the biotechnology company's stock worth $78,068,000 after buying an additional 324,703 shares during the period. Finally, CWA Asset Management Group LLC increased its position in Biogen by 11.2% during the third quarter. CWA Asset Management Group LLC now owns 42,412 shares of the biotechnology company's stock worth $9,580,000 after buying an additional 4,285 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Stock Performance

Shares of BIIB stock opened at $240.98 on Thursday. The stock has a market capitalization of $35.60 billion, a PE ratio of 42.65, a price-to-earnings-growth ratio of 2.71 and a beta of 0.09. Biogen Inc. has a 52-week low of $138.00 and a 52-week high of $244.65. The stock's 50-day moving average price is $221.92 and its 200 day moving average price is $205.19. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period in the prior year, the business earned $5.47 EPS. The firm's revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 12.31 EPS for the current year.

Wall Street Analyst Weigh In

BIIB has been the subject of a number of research reports. Guggenheim boosted their price objective on Biogen from $260.00 to $280.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Jefferies Financial Group restated a "buy" rating on shares of Biogen in a research report on Monday, July 13th. Seaport Research Partners upgraded shares of Biogen to an "outperform" rating in a research report on Monday, October 12th. Piper Sandler reaffirmed an "overweight" rating and issued a $245.00 target price (up from $225.00) on shares of Biogen in a report on Thursday, September 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Biogen from a "neutral" rating to an "overweight" rating and upped their price target for the company from $210.00 to $300.00 in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biogen presently has an average rating of "Moderate Buy" and a consensus target price of $240.86.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Positive kidney-disease data: Biogen highlighted 76-week EMPAVELI data showing sustained proteinuria reduction, stable kidney function and a consistent safety profile in C3G and primary IC-MPGN. Additional felzartamab and nephrology programs strengthened investor confidence in the company’s expanding renal franchise. Biogen nephrology data announcement
• Positive Sentiment: Higher analyst price target: Wells Fargo raised its BIIB target from $250 to $310 and maintained an “overweight” rating, signaling significant potential upside based on the company’s pipeline and growth prospects.
• Positive Sentiment: Earnings optimism: Zacks expects Biogen to beat consensus estimates in its upcoming third-quarter report, citing favorable earnings and revenue trends. The company is scheduled to report on October 28, making the release a near-term catalyst. Biogen earnings preview
• Positive Sentiment: Pipeline and strategic-growth expectations: Biogen is being featured among biotechnology companies with promising late-stage drug programs and upcoming regulatory or clinical milestones. The Apellis transaction is also expected to become increasingly accretive to adjusted earnings beginning in 2027. Zacks biotech pipeline commentary

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.